RTC 501
Alternative Names: RTC-501; RTC-501 IVTLatest Information Update: 31 Jul 2023
At a glance
- Originator Ripple Therapeutics
- Class Antiglaucomas; Eye disorder therapies; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Glaucoma
Most Recent Events
- 17 Jul 2023 Early research in Glaucoma in Canada (Intravitreous) before July 2023 (Ripple Therapeutics pipeline, July 2023)